Novartis au 2e trimestre: fortes ventes, croissance à deux chiffres du résultat opérationnel core et lancements de Zolgensma et de Piqray; prévision des ventes et du résultat revue à la hausse

NEXT STORY
Capnography Devices Market to cross USD 700 Mn by 2025: Global Market Insights, Inc.
PREV STORY
Forty Seven, Inc. Prices Underwritten Public Offering of 9,375,000 Shares of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Novartis au 2e trimestre: fortes ventes, croissance à deux chiffres du résultat opérationnel core et lancements de Zolgensma et de Piqray; prévision des ventes et du résultat revue à la hausse

NEXT STORY
Capnography Devices Market to cross USD 700 Mn by 2025: Global Market Insights, Inc.
PREV STORY
Forty Seven, Inc. Prices Underwritten Public Offering of 9,375,000 Shares of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon

SAN DIEGO, July 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Fluidigm Announces First Quarter 2019 Financial Results

author_avatar
NASDAQ Market News

Inovalon Reports Second Quarter 2019 Results

author_avatar
NASDAQ Market News